Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Jan, Vydra"'
Autor:
Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the
Externí odkaz:
https://doaj.org/article/613627563fa145bcad4718e937c66eed
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/3af9177edf0242ab84acd41478fdde4d
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe non-viral production of CAR-T cells through electroporation of transposon DNA plasmids is an alternative approach to lentiviral/retroviral methods. This method is particularly suitable for early-phase clinical trials involving novel typ
Externí odkaz:
https://doaj.org/article/77316501f7f440178ac5bdacf779f123
Autor:
Šárka Šestáková, Cyril Šálek, Dávid Kundrát, Ela Cerovská, Jan Vydra, Ivana Ježíšková, Adam Folta, Jiří Mayer, Petr Cetkovský, Hana Remešová
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Changes in DNA methylation are common events in the pathogenesis of acute myeloid leukemia (AML) and have been repeatedly reported as associated with prognosis. However, studies integrating these numerous and potentially prognosti
Externí odkaz:
https://doaj.org/article/445a337be93740f6998ac1681e644cb8
Autor:
Johannes Schetelig, Henning Baldauf, Falk Heidenreich, Jorinde D. Hoogenboom, Stephen R. Spellman, Alexander Kulagin, Thomas Schroeder, Henrik Sengeloev, Peter Dreger, Edouard Forcade, Jan Vydra, Eva Maria Wagner-Drouet, Goda Choi, Shankara Paneesha, Nuno A. A. Miranda, Alina Tanase, Liesbeth C. de Wreede, Vinzenz Lange, Alexander H. Schmidt, Jürgen Sauter, Joshua A. Fein, Yung-Tsi Bolon, Meilun He, Steven G. E. Marsh, Shahinaz M. Gadalla, Sophie Paczesny, Annalisa Ruggeri, Christian Chabannon, Katharina Fleischhauer
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor’s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in
Externí odkaz:
https://doaj.org/article/2b878953d63c4541a7adf722c396e6d2
Autor:
Frédéric Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)
Abstract The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cycl
Externí odkaz:
https://doaj.org/article/e846149530f94e79a96d37ec3420549b
Autor:
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Jan Vydra, Stefania Bramanti, Maija Itälä-Remes, Christoph Schmid, Alessandro Busca, Edouard Forcade, Werner Rabitsch, Marco Zecca, Nicolaus Kröger, Claude-Eric Bulabois, Giovanni Grillo, Alessandro Rambaldi, Renato Fanin, Francesco Zallio, Nicola Di Renzo, Yener Koc, Yana Novis, Andrew McDonald, Concepcion Herrera Arroyo, Jaime Sanz, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e920 (2023)
Availability of haploidentical donors has broadened utilization of allogeneic hematopoietic cell transplantation (allo-HCT). Peripheral blood stem cells (PBSC) are being used with increased frequency in haploidentical allo-HCT. We evaluated extent of
Externí odkaz:
https://doaj.org/article/a86fb26892d24374b8fde8eaa22d0625
Autor:
Martin Štach, Robert Pytlík, Kristýna Šmilauerová, Jana Rychlá, Martin Mucha, Jan Musil, Abhishek Koladiya, Matěj Nemec, Martina Petráčková, Iva Kaštánková, Pavla Pecherková, Lucie Šrámková, Kamila Polgárová, Marek Trněný, Petr Lesný, Jan Vydra, Pavel Otáhal
Publikováno v:
Pathology and Oncology Research, Vol 29 (2023)
Tisagenlecleucel (tisa-cel) is a CD19-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (n = 5), adult B-ALL (n = 2), and DLBCL (n =
Externí odkaz:
https://doaj.org/article/1d9dc7c6b478480589b2506dafb816b3
Autor:
Sjoerd J. F. Hermans, Jurjen Versluis, Myriam Labopin, Sebastian Giebel, Yvette van Norden, Ivan Moiseev, Didier Blaise, Jose L. Díez Martín, Ellen Meijer, Montserrat Rovira, Goda Choi, Anna Maria Raiola, Yener Koc, Péter Reményi, Jan Vydra, Nicolaus Kröger, Simona Sica, Massimo Martino, Gwendolyn van Gorkom, Patrice Chevallier, Alessandro Busca, Concepcion Herrera Arroyo, Eolia Brissot, Zinaida Peric, Arnon Nagler, Roni Shouval, Fabio Ciceri, Jan J. Cornelissen, Mohamad Mohty
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e846 (2023)
Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT)
Externí odkaz:
https://doaj.org/article/f3ecf1ce04e04a398237df8bf608faa2
Autor:
Sarka Nemeckova, Kamila Alexova-Zurkova, Petr Hainz, Jitka Krystofova, Jana Mackova, Katerina Roubalova, Marketa Stastna-Markova, Milena Vrana, Jan Vydra
Publikováno v:
Current Oncology, Vol 29, Iss 5, Pp 2928-2934 (2022)
Nucleophosmin (NPM1, B23) is a multifunctional phosphoprotein expressed in all tissues. The protein is mainly localized in nucleoli. In hematological malignancies, NPM1 belongs to commonly altered genes. Its mutation, always heterozygous, leads to th
Externí odkaz:
https://doaj.org/article/25cd0e5b37d34af998eeb9653ed9fb99